Non-Inferiority Study Comparing MINI WELL READY® and FineVision® in Patients With Cataract Surgery

Sponsor
SIFI SpA (Industry)
Overall Status
Terminated
CT.gov ID
NCT03060954
Collaborator
Opera CRO, a TIGERMED Group Company (Other)
8
2
2
12.8
4
0.3

Study Details

Study Description

Brief Summary

Interventional, Multicentre, controlled, randomized, single blind, twoarmed non-inferiority trial

Condition or Disease Intervention/Treatment Phase
  • Device: MINI WELL READY ®
  • Device: FINE VISION®
N/A

Detailed Description

To evaluate the non-inferiority of the progressive extended depth of focus Intraocular Lens MINI WELL READY® in terms of visual performance, quality of vision and subjective outcomes versus the trifocal Intraocular Lens FineVision® after a follow up period of 2-6 months.

Study Design

Study Type:
Interventional
Actual Enrollment :
8 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
A Multicentre, Controlled, Randomised, Single-blind, Two-armed Trial Evaluating the Visual Performance, Quality of Vision and Subjective Outcomes After Bilateral Implantation of MINI WELL Ready® or FineVision® in Patients With Cataract Surgery.
Actual Study Start Date :
Feb 10, 2019
Actual Primary Completion Date :
Mar 5, 2020
Actual Study Completion Date :
Mar 5, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: MINI WELL READY ®

BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY

Device: MINI WELL READY ®
BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY

Other: FineVision ®

FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY

Device: FINE VISION®
FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY

Outcome Measures

Primary Outcome Measures

  1. Defocus curve - binocular [6 months]

    Defocus curve assessment

Other Outcome Measures

  1. Refraction [6 months]

    Ocular refraction evaluation

  2. Visual Acuity Evaluation [6 months]

    Uncorrected Distance Visual Acuity (UDVA)

  3. Visual Acuity Evaluation [6 months]

    Corrected Distance Visual Acuity (CDVA) Uncorrected Intermediate Visual Acuity (UIVA)

  4. Visual Acuity Evaluation [6 months]

    Distance Corrected Intermediate Visual Acuity (DCIVA)

  5. Visual Acuity Evaluation [6 months]

    Uncorrected Near Visual Acuity (UNVA)

  6. Visual Acuity Evaluation [6 months]

    Distance Corrected Near Visual Acuity (DCNVA)

  7. Reading speed [6 months]

    Reading speed performance

  8. Halometry [6 months]

    Halos evaluation

  9. Contrast sensitivity [6 months]

    Contrast sensitivity evaluation

  10. Subject satisfaction questionnaire - VF-11R [6 months]

    Subject satisfaction questionnaire - VF-11R "revised version": Annex A: Subject's glasses independence and light dependence Annex B: Quality of Vision (QoV) questionnaire

  11. Operative Complications / Postoperative Complications / Adverse Event Assessment [6 months]

    Assessment of Operative Complications, Postoperative Complications, Adverse Events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years

  • Bilateral cataract surgery required, no other ocular comorbidities

  • Healthy corneas, not treated surgically

  • Available for second-eye surgery within 1 week of the initial operation

  • Spherical refraction between -8.00D and +6.00D

  • Willing to adhere to the study visit schedule

  • Normal anterior and posterior segments

  • Clear intraocular media - other than cataract

  • To benefit from a social security system before being enrolled

  • Written informed consent consistent with local regulation research in human subjects

Exclusion Criteria:
  • Any previous history of ocular trauma or prior ocular surgery (including previous cataract surgery and CLRIs)

  • Ocular comorbidities determining potential postoperative Visual Acuity less than 0.50 decimal (0.3 logMAR)

  • Expected to require retinal laser treatment

  • A history of retinal detachment or predisposition for such disorder

  • Psudoexfoliation

  • Abnormal pupil size and position

  • Pupil size > 7 mm under mesopic condition

  • Use of contact lenses 30 days before the preoperative visit

  • Corneal warpage (e.g. Keratoconus, Pellucid Marginal Corneal Degeneration or Keratoglobus)

  • Corneal astigmatism greater than 0.75D

  • Zonular laxicity

  • Absence of adequate capsular support for the implant of the intraocular lens in the capsular bag

  • Microphthalmus

  • Active ocular disease in the operative eye, for example, chronic uveitis, proliferative diabetic retinopathy, chronic glaucoma unresponsive to medication, corneal decompensation and corneal endothelial cell insufficiency (such as Fuch's endothelial dystrophy)

  • Suspected microbial infection

  • Irregularities and capsulorexis decentralization

  • Surgical difficulties that may increase the risk of complications such as persistent bleeding, significant iris damage, an uncontrollable intraocular hypertonia, or damage due to significant vitreous loss

  • Patients in whom the intraocular lens may interfere with the ability to observe, diagnose or treat diseases of the posterior segment

  • Patients in whom neither the posterior capsule nor the zonula can provide adequate support to the lens

  • Subjects with any systemic disease that could increase operative risk or confound the outcome

  • Pregnant or lactating or planning a pregnancy at the time of enrolment

  • Vulnerable subjects (children <18 years, people in guardianship or trusteeship or inability to give an informed consent)

  • Subjects participating in a concurrent clinical trial or if they have participated in an ophthalmology clinical trial within the last 30 days

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ophtalmologie Hôpital Morvan Brest France
2 Clinique Juge Marseille France 13008

Sponsors and Collaborators

  • SIFI SpA
  • Opera CRO, a TIGERMED Group Company

Investigators

  • Study Director: Gianluca Stivale, SIFI SpA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
SIFI SpA
ClinicalTrials.gov Identifier:
NCT03060954
Other Study ID Numbers:
  • PSM29
First Posted:
Feb 23, 2017
Last Update Posted:
Sep 3, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 3, 2020